Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Terminated Phase 2 Interventional

Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer

NCT01426620
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Blueberry powder
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 30, 2026, 4:51 PM EDT
Completed No phase listed Observational

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

NCT02135718
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Huntington Beach, California • Newport Beach, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feeding Study in Premature Infants

NCT00681018
View directory record Official record
Conditions
Premature Infants
Interventions
Liquid human milk fortifier, Powder human milk fortifier
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
Up to 40 Days
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 30, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

NCT00890318
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-072, ketoconazole, Placebo
Drug · Other
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 30, 2026, 4:51 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Flucanazole

NCT04502277
View directory record Official record
Conditions
Candidiasis
Interventions
Fluconazole Powder
Drug
Lead sponsor
Sutphin Drugs
Industry
Eligibility
18 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 30, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection

NCT06139224
View directory record Official record
Conditions
Alcohol Use Disorder, Human Immunodeficiency Virus
Interventions
4 week prebiotic consumption, 4 week placebo consumption
Dietary Supplement · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Dried Cranberry, Placebo Oral Capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Indoximod, Sipuleucel-T, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

NCT01467882
View directory record Official record
Conditions
Central Precocious Puberty
Interventions
Triptorelin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
2 Years to 9 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 30, 2026, 4:51 PM EDT
Recruiting Phase 4 Interventional

Placement of Antibiotic Powder in Wounds During the Emergency Room

NCT03765567
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution

NCT01966692
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate Formulation 1, Fluticasone Propionate Formulation 2, Fluticasone Propionate Formulation 3*
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT01257581
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
creatine, tamoxifen
Drug
Lead sponsor
Nazem Atassi
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Results available

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

NCT04992312
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon Nasal Powder [Baqsimi]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 30, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ataluren (PTC124) in Hemophilia A and B

NCT00947193
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

NCT02586493
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Jasper, Alabama • Clearwater, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

NCT04857307
View directory record Official record
Conditions
Epilepsy
Interventions
Alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Little Rock, Arkansas • Orlando, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 30, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

NCT03140280
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Freeze-Dried Black Raspberry Powder
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 30, 2026, 4:51 PM EDT